Your browser is no longer supported. Please, upgrade your browser.
Settings
CGIX Cancer Genetics, Inc. daily Stock Chart
CGIX [NASD]
Cancer Genetics, Inc.
Index- P/E- EPS (ttm)-2.98 Insider Own16.38% Shs Outstand2.11M Perf Week2.39%
Market Cap6.51M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float2.01M Perf Month-7.26%
Income-6.30M PEG- EPS next Q- Inst Own10.60% Short Float1.22% Perf Quarter-1.96%
Sales6.90M P/S0.94 EPS this Y22.70% Inst Trans-0.43% Short Ratio0.37 Perf Half Y-38.14%
Book/sh3.03 P/B0.99 EPS next Y- ROA- Target Price- Perf Year-51.60%
Cash/sh1.66 P/C1.81 EPS next 5Y40.00% ROE- 52W Range1.92 - 9.50 Perf YTD-49.66%
Dividend- P/FCF- EPS past 5Y41.70% ROI-59.00% 52W High-68.42% Beta2.12
Dividend %- Quick Ratio0.90 Sales past 5Y-6.50% Gross Margin49.20% 52W Low56.25% ATR0.26
Employees110 Current Ratio0.90 Sales Q/Q-22.20% Oper. Margin- RSI (14)48.96 Volatility7.46% 7.96%
OptionableNo Debt/Eq0.23 EPS Q/Q47.00% Profit Margin- Rel Volume0.32 Prev Close2.80
ShortableYes LT Debt/Eq0.02 Earnings- Payout- Avg Volume66.79K Price3.00
Recom3.00 SMA20-3.39% SMA50-4.35% SMA200-23.71% Volume21,217 Change7.14%
Dec-07-17Initiated Maxim Group Buy $6
Jun-27-17Initiated Dawson James Buy
Jun-26-17Initiated The Benchmark Company Speculative Buy $6
Sep-26-16Initiated Rodman & Renshaw Buy $6
Jun-24-20 05:30PM  
Jun-01-20 08:00AM  
May-12-20 06:37AM  
Feb-20-20 09:00AM  
Nov-20-19 08:00AM  
Nov-14-19 05:29AM  
Oct-24-19 04:15PM  
08:30AM  
Oct-17-19 06:55AM  
Aug-20-19 08:00AM  
Jul-16-19 12:44PM  
08:44AM  
Jul-15-19 04:22PM  
04:10PM  
Jun-25-19 07:24AM  
Jun-24-19 07:00AM  
Jun-05-19 02:00AM  
May-20-19 05:06PM  
05:00PM  
Apr-16-19 07:22AM  
07:00AM  
Mar-26-19 08:06AM  
Feb-14-19 07:04AM  
Jan-31-19 04:01PM  
Jan-29-19 07:25AM  
Jan-28-19 10:33PM  
04:00PM  
Jan-21-19 09:21AM  
Jan-16-19 08:45AM  
Jan-14-19 05:29PM  
Jan-10-19 08:27AM  
Jan-09-19 11:20PM  
04:00PM  
08:00AM  
Dec-17-18 08:00AM  
Dec-14-18 06:55AM  
Nov-21-18 08:04AM  
Nov-19-18 05:40PM  
04:33PM  
04:16PM  
Nov-14-18 04:01PM  
Nov-01-18 11:28AM  
Oct-18-18 09:05AM  
Oct-16-18 08:00AM  
Oct-08-18 07:00AM  
Sep-28-18 06:31PM  
Sep-25-18 04:01PM  
Sep-20-18 08:30AM  
Sep-18-18 12:14PM  
08:30AM  
Aug-29-18 11:54PM  
Aug-17-18 11:51AM  
Aug-14-18 07:49AM  
07:30AM  
06:30AM  
Aug-13-18 02:33PM  
Aug-07-18 04:05PM  
Jul-18-18 04:05PM  
Jul-12-18 07:25AM  
Jun-19-18 04:18PM  
Jun-12-18 08:00AM  
Jun-04-18 04:00PM  
01:30PM  
10:27AM  
Jun-01-18 08:00PM  
07:15PM  
04:06PM  
03:48PM  
May-31-18 04:30PM  
May-30-18 08:00PM  
06:21PM  
10:01AM  
May-29-18 01:23PM  
May-28-18 09:30AM  
May-26-18 07:51AM  
May-25-18 07:30AM  
May-24-18 07:33PM  
May-23-18 05:30PM  
10:08AM  
May-19-18 08:13AM  
May-17-18 01:40PM  
May-16-18 01:30PM  
10:06AM  
May-15-18 10:14AM  
09:37AM  
07:24AM  
07:00AM  
06:45AM  
May-12-18 07:46AM  
May-10-18 08:31PM  
04:05PM  
11:45AM  
10:00AM  
09:15AM  
May-09-18 05:15PM  
03:45PM  
May-08-18 06:40PM  
04:20PM  
12:19PM  
07:30AM  
Cancer Genetics, Inc., through its subsidiary, vivoPharm, Pty Ltd., provides contract research services primarily focusing on studies to guide drug discovery and development programs in the oncology and immuno-oncology fields. The company's clinical offerings include a portfolio of proprietary tests, such as comparative genomic hybridization microarrays and next generation sequencing panels, gene expression tests, and DNA fluorescent in situ hybridization probes targeting hematological, and human papillomavirus-associated cancers, which include cervical, anal, head, and neck cancers. It serves the biotechnology and pharmaceutical customers in the United States, Europe, and Australia. Cancer Genetics, Inc. was founded in 1999 and is headquartered in Rutherford, New Jersey.